Innovative Protein Folding Predictions

A Revolutionary Breakthrough in Precision Medicine

Based on the leading science of Dr. Neil Cashman, our proprietary target discovery engine utilizes two computational discovery technologies, ProMIS™ and Collective Coordinates, to predict and identify toxic misfolded proteins implicated in the development and progression of neurodegenerative and other misfolded protein diseases.

About Our Science

A Growing Portfolio of Selective Antibody Therapeutic Product Candidates

Our portfolio leverages a revolutionary approach that enables the tailoring of therapeutic antibodies with a high degree of selectivity for the key drivers of multiple neurodegenerative and other misfolded protein diseases, including:

  • Alzheimer’s disease (AD)
  • Multiple System Atrophy (MSA)
  • Amyotrophic lateral sclerosis (ALS)
  • Parkinson’s disease (PD)
View Product Pipeline

Addressing Neurodegenerative and Other Misfolded Protein Diseases Using Novel Biologic Products

We are ProMIS Neurosciences, a leading clinical-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. Our large team of multidisciplinary experts is committed to the discovery and development of selective antibody therapies that combat neurodegenerative and other misfolded protein diseases at the source.

About Our Company

Latest News

View All News

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference

ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

View All News

Stock Snapshot